One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
Home ➤ Press Releases ➤ GNI Group to Acquire Ayumi Pharmaceutical in Deal Valued at Approximately ¥44.8 Billion
GNI Group to Acquire Ayumi Pharmaceutical in Deal Valued at Approximately ¥44.8 Billion
GNI Group to Acquire Ayumi Pharmaceutical in Deal Valued at Approximately ¥44.8 Billion
  • Home ➤ Press Releases ➤ GNI Group to Acquire Ayumi Pharmaceutical in Deal Valued at Approximately ¥44.8 Billion

GNI Group to Acquire Ayumi Pharmaceutical in Deal Valued at Approximately ¥44.8 Billion

GNI Group Ayumi acquisition

Quick Navigation

  • Ayumi Brings Established Products and Commercial Capabilities
  • Acquisition Supports GNI Group’s Expansion in Japan
  • Company Leaders Outline Growth Plans
  • About GNI Group

GNI Group Co., Ltd. has agreed to acquire all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. The transaction values Ayumi at approximately ¥44.8 billion. It will make Ayumi a wholly owned subsidiary of GNI Group upon completion.

Announced on June 7, 2026, the GNI Group Ayumi acquisition is intended to expand the company’s pharmaceutical business in Japan. GNI Group expects Ayumi’s established products and nationwide commercial network to support the introduction of innovative therapies and biosimilars. Furthermore, it believes these resources will help introduce internally developed medicines into the Japanese market.

Following the transaction, GNI Group expects combined fiscal 2026 revenue to reach approximately ¥65.2 billion. This figure is a company forecast rather than an achieved financial result.

Ayumi Brings Established Products and Commercial Capabilities

Ayumi Pharmaceutical has an established position in Japan’s pain management and rheumatology markets, alongside products used in orthopedic care. Its nationwide commercial network serves healthcare institutions across the country.

According to the announcement, Ayumi’s flagship product, Calonal®, an acetaminophen medicine, holds more than 80% of Japan’s domestic acetaminophen market.

For the fiscal year ended March 2026, Ayumi reported consolidated revenue of approximately ¥38.5 billion and operating profit of approximately ¥6.2 billion. The company also provides contract manufacturing services. In addition, it maintains manufacturing and commercial operations in Japan.

Acquisition Supports GNI Group’s Expansion in Japan

GNI Group expects Ayumi to provide a larger recurring revenue platform in Japan and create opportunities for pharmaceutical licensing and commercialization. Moreover, Ayumi’s products, customer relationships, and distribution capabilities are expected to complement GNI Group’s existing drug development activities.

The company identified several potential benefits from the transaction:

  • Expanding its capabilities in pain management, rheumatology, and orthopedics.
  • Supporting the introduction of overseas pharmaceuticals and biosimilars into Japan.
  • Diversifying revenue across Japan, China, and the United States.
  • Strengthening cash generation and financial stability.
  • Creating opportunities for cross-selling and cooperation across the combined product portfolio.

GNI Group also expects the acquisition to expand its employee base, marketed products, and development pipeline. The combined business will focus on five therapeutic areas: fibrosis, pain management, rheumatology, oncology, and orthopedics.

Company Leaders Outline Growth Plans

Ying Luo, President and CEO of GNI Group, described the agreement as a milestone in the company’s strategy to build a cross-Pacific biopharmaceutical business. He said Ayumi’s commercial infrastructure and pain management portfolio would strengthen GNI Group’s ability to bring additional treatments to patients in Japan.

Luo also welcomed Blackstone, Toho, and Hisamitsu as new shareholders. He said the company looked forward to working with its stakeholders on the next phase of growth.

Atsuhiko Sakamoto, Head of Private Equity at Blackstone Japan, described Ayumi as Blackstone’s first controlling private equity investment in Japan. He said Blackstone had worked with Ayumi’s management to strengthen its business foundation, support growth, and establish its market position.

About GNI Group

GNI Group is a Japan-headquartered biopharmaceutical company with operations in Japan, China, the United States, and Australia. Its activities include drug discovery, pharmaceutical development and commercialization, and medical technology.

The company’s marketed products and development pipeline target fibrosis, cancer, inflammatory diseases, pain, and other serious conditions. GNI Group also holds a controlling interest in Gyre Therapeutics, Inc., a Nasdaq-listed U.S. biopharmaceutical company focused on fibrosis, inflammatory diseases, and cancer.

Related Press Releases

  • TechnoVision: Top 5 Tech Trends to Watch in 2027 By Capgemini
  • AGC Biologics Welcomes Multiple Cell Therapy Projects at Its New Yokohama Facility
  • BlackLine Launches Availability on Anthropic’s Claude Marketplace
  • Mobilicom Announces Participation in Upcoming Industry and Investor Conferences
  • AI Errors Strain Business Finances and Delay Projects Worldwide
  • Neurosterix, an Addex Spin-Out, Closes $105 Million Series B Financing
Latest report from the featured industries
  • Advanced Materials
    Optical Coating Market
    Spray Drying Equipment Market
    Metal Roofing Market
    Stone And Tile Adhesives And Sealants Market
    Armor Materials Market
    PTFE Hoses Market
    Roofing Materials Market
    Acrylic Foam Tape Market
    Oil Shale Market
    Pine-Derived Chemicals Market
  • Aerospace and Defence
    Satellite Launch Systems Market
    Satellite Communication In The Defense Sector Market
    Lyocell Fabric Market
    Bullet Proof Jacket Market
    Rescue Pole Market
    Police Baton Market
    Drone Battery Market
    Gunshot Detection System Market
    Military Electro-optical And Infrared Systems Market
    Multirotor Drone Market
  • Agriculture & Agri Products
    Mooring Systems Market
    Oilseed Processing Market
    Cut Flowers Market
    Cotton Processing Market
    Farm Equipment Rental Market
    Agricultural Variable Rate Technology Market
    Indoor Farming Technology Market
    Essential Oils And Plant Extract For Livestock Market
    Food Vacuum Machine Market
    Ornamental Horticulture Market
  • Apparel | Fashion & Accessories
    3D Printed Jewelry Market
    Cotton (Linter) Pulp Market
    Snow Boots Market
    Merchandise Designing Market
    Volleyball Shoes Market
    Smart Clothing Market
    Workwear Market
    Down Jacket Market 
    Decorated Apparel Market
    Dancewear Market
  • Artificial Intelligence
    AI-Based Defect Detection Software Market
    AI Vision For Manufacturing Market
    AI Training Data Lineage Software Market
    AI Portfolio And Pipeline Management Software Market
    AI In Testing Inspection And Certification Market
    Agentic AI Market
    AI In Telecommunication Market
    AI In Materials Science Market
    AI Data Labeling Market
    AI Data Center Power Consumption Market
✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • Our Clients
  • Media Mentions
  • Infographics
  • Statistics and Facts
  • Research Methodology
  • Why Choose Us?
Secured Payment Options
Secured Payment Options

© 2026 Market.Us. All Rights Reserved.